We are live on
!
Find out more
Frazier Life Sciences Management Portfolio holdings
AUM
$4.59B
Turnover
20.45%
1-Year Est. Return
237.58%
This Fund
S&P 500
This Quarter
Est. Return
+25.98%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.67B
AUM Growth
+$293M
(+21%)
Cap. Flow
+$59.1M
Cap. Flow
% of AUM
3.53%
Top 10 Holdings %
Top 10 Hldgs %
66.82%
Holding
53
New
4
Increased
12
Reduced
8
Closed
5
Avg Time Held
0.9
years
Top 10 Avg Time Held
1
year
Top 20 Avg Time Held
0.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Disc Medicine
IRON
|
+$23.2M |
| 2 |
NewAmsterdam Pharma
NAMS
|
+$20.3M |
| 3 |
Phathom Pharmaceuticals
PHAT
|
+$19.6M |
| 4 |
Mirum Pharmaceuticals
MIRM
|
+$13.3M |
| 5 |
BridgeBio Pharma
BBIO
|
+$12.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
+$11.6M |
| 2 |
Vaxcyte
PCVX
|
+$11M |
| 3 |
RNAM
Avidity Biosciences
RNAM
|
+$7.67M |
| 4 |
Cogent Biosciences
COGT
|
+$7.55M |
| 5 |
Gritstone bio, Inc. Common Stock
GRTS
|
+$6.46M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.94% |
| 2 | Miscellaneous | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
DELISTED
HilleVax
HLVX
| $168M | 10.04% |
9,781,472
| – | – |
2022 Q2
4 quarters
|
|
|
KDNY
2
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $167M | 9.97% |
4,345,559
| – | – |
2022 Q1
5 quarters
|
|
|
3
Phathom Pharmaceuticals
PHAT
$599M
| $145M | 8.65% |
10,109,279
+1,702,127
| +20% | +$19.6M |
2022 Q1
5 quarters
|
|
|
4
NewAmsterdam Pharma
NAMS
$2.39B
| $129M | 7.72% |
10,871,803
+1,530,252
| +16% | +$20.3M |
2022 Q4
2 quarters
|
|
5
Krystal Biotech
KRYS
$9.79B
| $116M | 6.94% |
990,260
+44,853
| +5% | +$4.58M |
2022 Q1
5 quarters
|
|
|
6
Mirum Pharmaceuticals
MIRM
$5.19B
| $113M | 6.74% |
4,360,107
+500,000
| +13% | +$13.3M |
2022 Q1
5 quarters
|
|
7
Arcutis Biotherapeutics
ARQT
$3.32B
| $82.8M | 4.94% |
8,684,232
| – | – |
2022 Q1
5 quarters
|
|
8
Syndax Pharmaceuticals
SNDX
$1.21B
| $77.6M | 4.64% |
3,708,838
| – | – |
2022 Q1
5 quarters
|
|
|
VRNA
9
DELISTED
Verona Pharma
VRNA
| $62.2M | 3.72% |
2,944,349
| – | – |
2022 Q3
3 quarters
|
|
|
10
Vaxcyte
PCVX
$10.6B
| $58.2M | 3.47% |
1,164,405
-233,000
| -17% | -$11M |
2022 Q1
5 quarters
|
|
11
Rhythm Pharmaceuticals
RYTM
$5.97B
| $35.7M | 2.13% |
2,167,222
+2,483
| +0.1% | +$44.8K |
2022 Q3
3 quarters
|
|
|
12
BridgeBio Pharma
BBIO
$12.7B
| $34.2M | 2.04% |
1,988,876
+817,226
| +70% | +$12.3M |
2023 Q1
1 quarter
|
|
13
Tarsus Pharmaceuticals
TARS
$3.38B
| $32.3M | 1.93% |
1,787,527
| – | – |
2022 Q1
5 quarters
|
|
14
DELISTED
Alpine Immune Sciences Inc
ALPN
| $30.7M | 1.83% |
2,985,757
| – | – |
2022 Q1
5 quarters
|
|
15
DELISTED
KalVista Pharmaceuticals
KALV
| $29.1M | 1.74% |
3,238,859
| – | – |
2022 Q1
5 quarters
|
|
|
16
Disc Medicine
IRON
$2.14B
| $29.1M | 1.74% |
+655,000
| New | +$23.2M |
2023 Q2
0 quarters
|
|
17
DELISTED
Crinetics Pharmaceuticals
CRNX
| $25.5M | 1.52% |
1,414,823
| – | – |
2022 Q1
5 quarters
|
|
18
Revolution Medicines
RVMD
$41.5B
| $22.9M | 1.37% |
854,484
| – | – |
2023 Q1
1 quarter
|
|
|
THRX
19
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $21M | 1.25% |
2,248,194
| – | – |
2022 Q4
2 quarters
|
|
20
Acadia Pharmaceuticals
ACAD
$3.32B
| $20.5M | 1.23% |
857,338
| – | – |
2022 Q3
3 quarters
|
|
21
DELISTED
Merus
MRUS
| $19.7M | 1.17% |
746,479
| – | – |
2022 Q1
5 quarters
|
|
22
AnaptysBio
ANAB
$1.4B
| $18.3M | 1.09% |
899,700
| – | – |
2022 Q1
5 quarters
|
|
|
23
Cogent Biosciences
COGT
$4.88B
| $17.8M | 1.06% |
1,501,383
-657,771
| -30% | -$7.55M |
2022 Q1
5 quarters
|
|
24
Tyra Biosciences
TYRA
$1.29B
| $17.5M | 1.05% |
1,028,013
-393,297
| -28% | -$5.7M |
2022 Q1
5 quarters
|
|
25
Jade Biosciences
JBIO
$855M
| $17.1M | 1.02% |
28,425
+18,765
| +194% | +$12M |
2023 Q1
1 quarter
|
|
Similar funds
BWA
TYCC
Frazier Life Sciences Management's Q2 2023 Portfolio in Review
As of Q2 2023, Frazier Life Sciences Management held 53 positions worth $1.67B, up 21% from $1.38B the previous quarter. Its ten largest holdings account for 67% of the portfolio.
Frazier Life Sciences Management deployed $59.1M of net new capital in Q2 2023, opening 4 new positions and adding to 12 existing holdings. Its largest new stake was Disc Medicine: 655,000 shares worth $29.1M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Vaxcyte, an estimated $11M trimmed.
- Frazier Life Sciences Management's largest Q2 2023 buy was Disc Medicine: 655,000 shares worth $29.1M.
- Frazier Life Sciences Management added most to NewAmsterdam Pharma in Q2 2023, an estimated $20.3M increase.
- Frazier Life Sciences Management's biggest Q2 2023 reduction was Vaxcyte, cutting an estimated $11M.
- Frazier Life Sciences Management fully exited VectivBio Holding AG Ordinary Shares in Q2 2023, selling an estimated $11.6M.
- Frazier Life Sciences Management's ten largest holdings make up 67% of its $1.67B portfolio in Q2 2023.
- Frazier Life Sciences Management opened 4 new positions and closed 5 in Q2 2023.
- Frazier Life Sciences Management's portfolio value rose 21% quarter-over-quarter to $1.67B.
Based on Frazier Life Sciences Management's 13F filing for Q2 2023, filed 14 Aug 2023.